Reverse kidney damage: A breakthrough treatment that may transform kidney treatment |
Kidney disease has long been considered a progressive and irreversible condition, where treatment focuses only on slowing decline…
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
MannKind If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under…
Genetic risk scores fail to predict survival after diagnosis
New research across seven global biobanks shows that the DNA driving disease onset does not determine survival; instead,…
Doctor explains how painkillers can cause nephrotoxicity
It is common knowledge that overconsumption of water is capable of preventing the damages that are caused on…
Health Canada approves Ozempic® to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
Ozempic® is the first-and-only medication indicated for both the once-weekly treatment of adult patients with type 2 diabetes…